Navigation Links
FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
Date:7/1/2011

s from these highly preventable surgical complications."

About XARELTO® (rivaroxaban tablets)

XARELTO® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in people undergoing knee or hip replacement surgery. XARELTO® belongs to a group of medicines called anticoagulants. It works by blocking the blood clotting Factor Xa and thereby reduces the tendency of the blood to form clots. XARELTO® is the third New Drug Application the U.S. FDA has approved from the Janssen Pharmaceutical Companies this year.

Additionally, XARELTO® is being evaluated for the prevention and treatment of a broad range of disorders in which blood clotting plays a major role. The extensive program of clinical trials evaluating rivaroxaban makes the compound the most studied oral, Factor Xa inhibitor in the world today. By the time of its completion, more than 65,000 patients will have participated in the rivaroxaban clinical development program. Rivaroxaban is being developed jointly by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare.

Important Safety Information

WHAT IS XARELTO®?

XARELTO® (rivaroxaban tablets) is a prescription medicine used to help prevent blood clots from forming in patients after hip or knee replacement surgery.

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO®?

  • You should take XARELTO® exactly as directed by your doctor
  • Do not skip a dose or stop taking XARELTO® unless you are advised to do so by your doctor. Stopping may increase your risk of a blood clot
  • If a dose is missed, take XARELTO® as soon as possible and continue on the following day, taking XARELTO® as directed by your doctor. Do not take two doses at the same time
  • XARELTO® can cause b
    '/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
2. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
3. FDA Approves Nulojix for Kidney Transplant Patients
4. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
5. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
6. FDA Approves Redesigned Labels for Some Merck Drugs
7. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
8. FDA Approves Marketing of RMS Subcutaneous Needle Sets
9. FDA Approves Injectable Gel to Treat Fecal Incontinence
10. FDA approves Incivek for hepatitis C
11. FDA Approves Sutent for Rare Type of Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Syneron Medical Ltd. (NASDAQ: ELOS ... that its new PicoWay® device has received CE Mark ... and pigmented lesions on any skin type. PicoWay is ... and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay technology ... are trillionths of a second, known as picosecond pulses. ...
(Date:7/28/2014)... (NYSE: RMD ), an innovator and pioneer ... and other chronic respiratory conditions, has won a permanent ... medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales ... 220 masks.  The judgment was entered by the Regional ... appealable, and applies throughout Germany.  The ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 ... to meet with Linde,s Healthcare division experts at ... held at McCormick Place in Chicago, Illinois ... demand nothing less than complete confidence in a reliable ... Healthcare Segment manager. "Linde understands the importance of this ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Eli Lilly and Company,s (NYSE: LLY ... set to launch. Through the program, the company is ... that often lack basic resources. While serving others, the ... of different cultures and see firsthand the complex problems ...
... 2011 Patient Safety Technologies, Inc. (the "Company") (OTC ... closing of a $7.1 million common stock financing.  The ... several existing shareholders and certain members of senior management, ... price of $0.75 per share.  Proceeds from the offering ...
Cached Medicine Technology:Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments 2Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments 3Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments 4Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments 5Patient Safety Technologies, Inc. Closes $7.1 Million Common Stock Offering 2
(Date:7/28/2014)... An estimated 68,000 women and men ... and prostate cancers – an aggressive form of the ... other parts of the body, such as the lungs, ... University College of Medicine have developed a compound ... progression by blocking tumor cells from “re-seeding.” Their discovery ...
(Date:7/28/2014)... Randy Dotinga HealthDay ... Scientists know it takes humans just milliseconds to look at ... Now, a new study finds that certain facial features seem ... The shape and size of the mouth, for example, ... dimensions are keys to attractiveness. The study findings ...
(Date:7/28/2014)... treat severe chronic migraine headaches led to significant symptom ... patients treated at Massachusetts General Hospital (MGH). Physicians ... report that more than half of 35 patients treated ... headaches associated with compression of craniofacial nerves reported ... paper has received advance online publication in the journal ...
(Date:7/28/2014)... 2014 Thousands of DePuy Pinnacle hip ... individuals who were allegedly injured by a metal-on-metal version ... forward in U.S. District Court, Northern District of Texas, ... on July 18, 2014, U.S. District Judge Ed Kinkeade ... Plaintiffs’ Steering Committee that sought the deposition of a ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Glutamine is ... and it’s considered to be conditionally essential during times ... is an advanced recovery & Immune System Support. , ... glutamine your body produces, supplementing with additional glutamine may ... waste products in the body, digestion and immune system ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... be involved in decisions regarding quality of the donor ... a higher risk of failure, according to research by ... of patients would choose to remain on the waiting ... to the study,s lead author Michael L. Volk, M.D., ...
... (HealthDay News) -- ,The timing of an operation doesn,t affect ... study finds. For example, there,s no difference in death ... morning or on Monday instead of Friday, the researchers said. ... lead to a higher rate of safety problems when operations ...
... with obstructive sleep apnea are more likely to stick ... involved with their treatment, according to a team of ... airway collapses during sleep. It is the most common ... become more elevated in obese people. The first line ...
... Optimism is associated with higher grades for female students, but ... at Ben-Gurion University of the Negev in Israel assessed the ... 72 percent female) aged 20 to 28. The investigators ... grades than those who were less optimistic. However, high levels ...
... a chronic swelling condition common in breast cancer survivors, ... past, most people believed that exercise might induce or ... researchers say the benefits of exercise outweigh the risks ... Jane Armer, professor in the Sinclair School of Nursing, ...
... issue of Hepatology , a journal of the ... uncovered limitations in screening for primary liver cancer, also ... that, if given the choice during a clinical trial, ... of non-screening, therefore making a randomized study of HCC ...
Cached Medicine News:Health News:Transplant candidates seek best quality livers, even if it means waiting longer 2Health News:Time of Surgery Doesn't Influence Results, Study Says 2Health News:Innovative approaches help sleep apnea sufferers benefit from CPAP 2Health News:MU researchers recommend exercise for breast cancer survivors, lymphedema patients 2Health News:Studies of patients with cirrhosis uncover limitations in liver cancer screening 2
Irrigation pump for arthroscopy....
... DVD Burner captures still images and ... patient archives allows for multiple cases ... The unit provides software burned to ... playback and editing. Compatible with DICOM ...
The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements....
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty....
Medicine Products: